Azithromycin-Induced Proarrhythmia and Cardiovascular Death

Annals of Pharmacotherapy

Volumn 47, Issue 11, 2013, Pages 1547-1551

  Howard, Patricia A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Azithromycin; cardiovascular risk; proarrhythmia; QT prolongation

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CIPROFLOXACIN; LEVOFLOXACIN; MAGNESIUM SULFATE; PENICILLIN DERIVATIVE; PENICILLIN V; SULBACTAM;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA CHRONICUM MIGRANS; HEART PROARRHYTHMIA; HUMAN; INTERSTITIAL PNEUMONIA; MEDLINE; MIDDLE AGED; OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; TORSADE DES POINTES; VIRUS PNEUMONIA;

AZITHROMYCIN; CARDIOVASCULAR RISK; PROARRHYTHMIA; QT PROLONGATION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; HUMANS; LONG QT SYNDROME; OBSERVATIONAL STUDY AS TOPIC; RISK FACTORS; TORSADES DE POINTES;

EID: 84888985056     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013504905     Document Type: Review

References (18)

1. Antzelevitch C,Sun ZQ,Zhang ZQ,et al.Cellular and ionic mechanism underlying erythromycin induced long QT intervals and torsade de pointes.J Am Coll Cardiol. 1996;28:1836-1848.
2. Cetin M,Yildirimer M,Ozen S,Tanriverdi S,Coskun S.Clarithromycin-induced long QT syndrome: a case report.Case Rep Med. 2012;2012:634-652.
3. Milberg P,Eckardt L,Bruns HJ,et al.Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.J Pharmacol Exp Ther. 2002;303:218-225.
4. Zithromax (azithromycin) [product information]. New York, NY: Pfizer Labs. http://www.pfizer.com/products/rx/rx_product_zithromax.jsp. Accessed August 1, 2013.
5. Samarendra P,Kumari S,Evan SJ,Sacchi TJ,Navarro V.QT prolongation associated with azithromycin/amiodarone combination.Pacing Clin Electrophysiol. 2001;24:1572-1574.
6. Matsunaga N,Oki Y,Prigollini A.A case of QT-interval prolongation precipitated by azithromycin.N Z Med J. 2003;116:U666.
7. Kim MH,Berkowitz C,Trohman RG.Polymorphic ventricular tachycardia with a normal QT interval following azithromycin.Pacing Clin Electrophysiol. 2005;28:1221-1222.
8. Kezerashvili A,Khattak H,Barsky A,Nazari R,Fisher JD.Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors.J Interv Card Electrophysiol. 2007;18:243-246.
9. Huang BH,Wu CH,Hsia CP,Chen CY.Azithromycin-induced torsade de pointes.Pacing Clin Electrophysiol. 2007;30:1579-1582.
10. Russo V,Puzio G,Siniscalchi N.Azithromycin-induced QT prolongation in elderly patient.Acta Biomed. 2006;77:30-32.
11. Strle F,Maraspin V.Is azithromycin treatment associated with prolongation of the Q-Tc interval?.Wien Klin Wochenschr. 2002;114:396-399.
12. Ray WA,Murray KT,Hall K,Arbogast PG,Stein CM.Azithromycin and the risk of cardiovascular death.N Engl J Med. 2012;366:1881-1890.
13. Svanström H,Pasternak B,Hviid A.Use of azithromycin and death from cardiovascular causes.N Engl J Med. 2013;368:1704-1712.
14. Foulds G,Shepard RM,Johnson RB.The pharmacokinetics of azithromycin in human serum and tissue.J Antimicrob Chemother. 1990;:73-82.
15. Rautaharju PM,Zhou SH,Wong S,et al.Sex differences in the evolution of the electrocardiographic QT interval with age.Can J Cardiol. 1992;8:690-695.
16. Sagie A,Larson MG,Goldberg RJ,Bengston JR,Levy D.An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study).Am J Cardiol. 1992;70:797-801.
17. Food and Drug Administration. FDA statement regarding azithromycin (Zithromax) and the risk of cardiovascular deathMay17, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm304372.htm. Accessed August 2, 2013.
18. Food and Drug Administration. FDA drug safety communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. March12, 2013. http://www.fda.gov/Drugs/DrugSafety/ucm341822.htm. Accessed August 2, 2013.